And complexed with an inhibitor of the fourth anilinoquinazoline J Biol Chem 2002, 277:46265 46 272. I Stancovski Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the counter-rotating Ufigen effects of monoclonal rpern against ErbB2 receptor on tumor growth. Proc Natl Acad Sci U.S. A. 1991, 88:8691 8695th SB939 Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, et al. Anti-HER2 old K Body Nonfucosylated Addicted t depends abh-Dependent cellular Cytotoxicity re t re t in patients with breast cancer. Clinical Cancer Research. 2007, 13:1875 1882nd Tagliabue E, F Centis, Campiglio M, Mastroianni A, S Martignone, Pellegrini R, et al. W Select the recoverable monoclonal Body, internalization and phosphorylation of p185HER2 and induce cell growth inhibition with HER2/neu gene amplification.
Int J Cancer. 1991, 47:933 with 937th Takai N, Jain A, Kawamata N, Popoviciu LM JW, Whittaker S, et al. 2C4, a monoclonal antique Old body against HER2 St, Rt signaling pathways HER-kinase and inhibits the growth of ovarian cancer cells. Cancer. 2005, 104:2701 2708th Oncogene Moasser Page 2-Methoxyestradiol 20th Author manuscript 6th, April 2011 PMC. Tan AR, Yang X, Hewitt SM, Berman A, ER Lepper, Sparreboom A, et al. The evaluation of the biological parameters and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor tyrosine kinase inhibitor. J Clin Oncol. 2004, 22:3080 3090th Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, et al. Produced in vitro and in vivo anti-tumor activity T a K Rpers humanized monoclonal against c erbB second Br J Cancer.
1996, 73:1362 1365th Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Intestinal neoplasia combinatorial Chemopr action. Nat Med 2000, 6:1024 1028th Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: twice family receptor/ErbB2 epidermal growth factor and replaced Vaskul endothelial growth factor receptor tyrosine kinase inhibitor of the anti-tumor and anti-angiogenesis t. Cancer Res 2004, 64:4931 4941st Traxler P, Bold G, Buchdunger E, G Caravatti, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design of clinical trials. Med Res Rev 2001, 21:499 512th Tsou HR, Overbeek Klumpers CE, Hallett WA, Reich MF, Floyd MB, Johnson BD, et al.
Optimization of 6,7-disubstituted quinoline fourth M Rz urenitrile as orally active, irreversible inhibitors of the human epidermal growth factor, t-2 receptor kinase. J Med Chem 2005, 48:1107 1131st LF van, van dV, Loman J, van DL, Jenster G, Akiyama T, et al. Mutation of the human neu protein erm glicht Low modulation index Rpern monoclonal antique Body. Oncogene. 1990, 5:497 503rd Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2 overexpressing metastatic. J Clin Onc. 2002, Wakeling AE 20:719 726th, Guy SP, Woodburn JR, Ashton SE, Curry FOJ, Barker AJ, et al. ZD1839: an oral epidermal signaling with potential for cancer therapy. Cancer Research. 2002, 62:5749 5754th Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, et al. Treatment of his models with overexpression of HER-2/neu in breast cancer xenograft with trastuzu